Sandu Pharmaceuticals Ltd
Sandu Pharmaceuticals Ltd (SANDUPHQ) last traded at ₹38, a market capitalisation of ₹36.7 crore, on a P/E of 23.7. Over the past 52 weeks the stock has ranged between ₹30 and ₹50.5. Sandu Pharmaceuticals Ltd last reported results for the quarter ended Mar 2025, with sales of ₹14.07 crore and net profit of ₹0.33 crore. Sandu Pharmaceuticals Ltd’s annual general meeting is scheduled for 11 Sept 2026. Figures are as of 25 Aug 2026 and are not real time.
Sandu Pharmaceuticals Ltd share price and key metrics
Metrics as of 25 Aug 2026. Not real time.
Sandu Pharmaceuticals Ltd quarterly results
In the quarter ended Mar 2025, sales were ₹14.07 cr, down 9.8% from ₹15.6 cr a year earlier. Net profit was ₹0.33 cr, down 44.1% year on year.
| ₹ crore | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|
| Sales | 17.66 | 16.61 | 17.43 | 15.6 | 17.05 | 17.7 | 18.37 | 14.07 |
| Expenses | 17.31 | 15.79 | 16.92 | 14.99 | 16.64 | 16.79 | 17.37 | 13.62 |
| Operating profit | 0.35 | 0.82 | 0.51 | 0.61 | 0.41 | 0.91 | 1 | 0.45 |
| OPM % | 1.98% | 4.94% | 2.93% | 3.91% | 2.40% | 5.14% | 5.44% | 3.20% |
| Other income | 0 | 0.09 | 0.03 | 0.31 | 0.04 | 0.03 | 0.02 | 0.07 |
| Interest | 0.02 | 0.01 | 0.02 | 0.01 | 0.02 | 0.03 | 0.03 | 0.03 |
| Depreciation | 0.12 | 0.13 | 0.14 | 0.19 | 0.16 | 0.17 | 0.19 | 0.15 |
| Profit before tax | 0.21 | 0.77 | 0.38 | 0.72 | 0.27 | 0.74 | 0.8 | 0.34 |
| Tax % | 47.62% | 27.27% | 44.74% | 16.67% | 40.74% | 32.43% | 30.00% | 2.94% |
| Net profit | 0.11 | 0.55 | 0.21 | 0.59 | 0.17 | 0.5 | 0.56 | 0.33 |
| EPS (₹) | 0.11 | 0.57 | 0.22 | 0.61 | 0.18 | 0.52 | 0.58 | 0.34 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Sandu Pharmaceuticals Ltd annual results
| ₹ crore | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|
| Sales | 65.5 | 65.35 | 67.28 | 67.19 |
| Operating profit | 2.88 | 2.48 | 2.3 | 2.76 |
| OPM % | 4.40% | 3.79% | 3.42% | 4.11% |
| Net profit | 1.59 | 1.52 | 1.46 | 1.55 |
| EPS (₹) | 1.80 | 1.57 | 1.51 | 1.60 |
TTM is the trailing twelve months to the most recent quarter.
Sandu Pharmaceuticals Ltd growth and returns
- 10 Years
- %
- 5 Years
- %
- 3 Years
- 1%
- TTM
- 0%
- 10 Years
- %
- 5 Years
- %
- 3 Years
- -1%
- TTM
- 6%
- 10 Years
- 3%
- 5 Years
- -6%
- 3 Years
- -13%
- 1 Year
- -23%
- 10 Years
- %
- 5 Years
- %
- 3 Years
- 4%
- Last Year
- 4%
Sandu Pharmaceuticals Ltd shareholding pattern
Promoters held 37.79% at Jun 2026, down from 42.91% at Jun 2025. DIIs 0.01%.
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 42.91% | 42.91% | 42.91% | 42.91% | 42.91% | 37.79% | 37.79% | 37.79% |
| DIIs | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% |
| Public | 57.09% | 57.09% | 57.09% | 57.08% | 57.09% | 62.19% | 62.20% | 62.20% |
| No. of shareholders | 10,246 | 10,333 | 10,287 | 10,226 | 10,284 | 10,284 | 10,298 | 10,268 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
When is Sandu Pharmaceuticals Ltd’s AGM?
Sandu Pharmaceuticals Ltd’s annual general meeting is scheduled for 11 Sept 2026.
- AGM41st Annual General Meeting and dividend eligibility
See the full results calendar for every Indian company reporting in the next 30 days.
Sandu Pharmaceuticals Ltd corporate filings
- Newspaper Advertisement intimating shareholders about Notice of Annual General Meeting and EvotingCompany Updatelow impact
Cruxal's analysis: Sandu Pharmaceuticals has published a newspaper advertisement to inform shareholders…
Read the full analysis - Letters to shareholders on annual report weblink whose email ids are not registered with the company/RTACompany Updatelow impact
Cruxal's analysis: Sandu Pharmaceuticals Ltd has issued a communication to shareholders whose email…
Read the full analysis - 41st Annual Report of Sandu Pharmaceuticals LimitedOtherslow impact
Cruxal's analysis: Sandu Pharmaceuticals has filed its 41st Annual Report for the financial year ending…
Read the full analysis - Intimation about Annual General MeetingAGM/EGMmedium impact
Cruxal's analysis: Sandu Pharmaceuticals Limited has scheduled its 41st Annual General Meeting for September…
Read the full analysis - Newspaper Advertisement Pre despatch of Annual Report intimation to ShareholdersCompany Updatelow impact
Cruxal's analysis: Sandu Pharmaceuticals Ltd has published a mandatory newspaper advertisement confirming…
Read the full analysis - Newspaper Publication Unaudited Financials for Q ended 30th June 2026Company Updatelow impact
Cruxal's analysis: Sandu Pharmaceuticals Limited reported its unaudited financial results for the quarter…
Read the full analysis - approval of material related party transactions subject to approval of shareholderCompany Updatelow impact
Cruxal's analysis: Sandu Pharmaceuticals has announced that it will seek shareholder approval for material…
Read the full analysis - statement of deviation and utlisation of funds for q ended 30.06.2026Company Updatelow impact
Cruxal's analysis: Sandu Pharmaceuticals Ltd has submitted its statement of deviation or variation in the…
Read the full analysis - Intimation about the date of the annual General MeetingCompany Updatelow impact
Cruxal's analysis: Sandu Pharmaceuticals Ltd has issued an intimation regarding the date of its upcoming…
Read the full analysis - Intimation about the Record dateCorp. Actionlow impact
Cruxal's analysis: Sandu Pharmaceuticals Ltd has issued an intimation regarding a record date for a…
Read the full analysis - Outcome of the Board Meeting 11.08.2026Company Updatemedium impact
Cruxal's analysis: Sandu Pharmaceuticals Limited reported Q1 FY27 revenue from operations of 16.39 crore…
Read the full analysis - Outcome of the Board MeetingBoard Meetingmedium impact
Cruxal's analysis: Sandu Pharmaceuticals Limited reported Q1 FY27 revenue from operations of 16.39 crore, a…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Track Sandu Pharmaceuticals Ltd
Cruxal reads every Sandu Pharmaceuticals Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.